Drug test to qualitatively assess the cells expressing the CD16 - Vietnam Registration 2403154ĐKLH/BYT-HTTB
Access comprehensive regulatory information for Drug test to qualitatively assess the cells expressing the CD16 in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại C medical device is registered under number 2403154ĐKLH/BYT-HTTB and manufactured by Becton, Dickinson and Company, BD Biosciences. The authorized representative in Vietnam is VĂN PHÒNG ĐẠI DIỆN BECTON DICKINSON ASIA LIMITED TẠI THÀNH PHỐ HỒ CHÍ MINH.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
2403154ĐKLH/BYT-HTTB
000.00.04.G18-220616-0009
BD CD16 (NKP15) FITC
335035
Technical Details
CD16 (NKP15) is used in in vitro diagnosis to determine the presence of CD16 antigen-expressing cells in peripheral blood, using the BD FACSLyric™ flow cytometry analyzer. Clinical Applications: Expression of the CD16 antigen in the characteristics of individuals with or suspected of having acute myeloid leukemia. CD16 (NKP15) is a qualitative test reagent intended for use only in laboratories.
Dates and Status
Nov 02, 2024